
INVICTA
Invicta Diagnostic Limited
- IPO Status
- Closed
- Open Date
- 1 Dec 2025
- Close Date
- 3 Dec 2025
IPO Details
- Min. Investment
- ₹2,72,000
- Price Band
- ₹80 - ₹85
- Lot Size
- 1600 shares
- Issue Size
- ₹28 Cr
- Face Value
- 10
- IPO Doc
- —
Schedule
- IPO open1 Dec 2025
- IPO close date3 Dec 2025
- Allotment date4 Dec 2025
- Funds unblock or debit5 Dec 2025
- Listing date8 Dec 2025
Financial Performance
- Revenue
- Profit
Stocks similar to INVICTA
- Vijaya Diagnostic Centre Limited
- Krsnaa Diagnostics Limited
FAQs
Invicta Diagnostic Limited IPO is a SME IPO aggregating up to ₹28 Cr, with equity shares of face value ₹10 each. The shares are proposed to be listed on NSE.
The Invicta Diagnostic Limited IPO opened on 1 Dec 2025 and closed on 3 Dec 2025. IPO Period: 1 Dec 2025 – 3 Dec 2025.
The price band for the Invicta Diagnostic Limited IPO is ₹80 to ₹85 per share. Investors can bid within the specified price band, subject to the applicable IPO rules.
The minimum lot size is 1,600 shares. At the upper price band of ₹85, the minimum investment required is ₹2,72,000.
Particular Details Lot Size 1,600 shares Minimum Application 3,200 shares Price Band ₹80 – ₹85 Minimum Investment ₹2,72,000 Here is the timeline for the Invicta Diagnostic Limited IPO:
IPO Event Date IPO Opens 1 Dec 2025 IPO Closes 3 Dec 2025 UPI Mandate Deadline 3 Dec 2025, 5:00 PM Basis of Allotment 4 Dec 2025 Refund Initiation 5 Dec 2025 Shares Credited 5 Dec 2025 Listing Date 8 Dec 2025 The basis of allotment for the Invicta Diagnostic Limited IPO is expected to be finalised on 4 Dec 2025. Investors can check their allotment status through the registrar or relevant stock exchange website using their application details. Registrar: Bigshare Services.
The equity shares of Invicta Diagnostic Limited are proposed to be listed on NSE. Proposed Listing Date: 8 Dec 2025.
The key financial performance of Invicta Diagnostic Limited is:
Financial Year Revenue Profit FY24 ₹7.99 Cr ₹2.69 Cr FY25 ₹30.1 Cr ₹4.89 Cr FY26 ₹32.35 Cr ₹4.91 Cr Revenue CAGR: 101.2% | Profit CAGR: 35.1%. Figures are as disclosed in the company's offer documents.


